Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.38 |
| ▸ | RHEB | Q15382 | 4/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38650836 | 0.85 | P2RX7 (0.36) | P2RX7RHEBAHRF7LTA4H | |
| SCHEMBL19014001 | 0.82 | P2RX7 (0.41) | P2RX7RHEB | |
| SCHEMBL8528724 | 0.82 | P2RX7 (0.40) | P2RX7RHEB | |
| SCHEMBL8526249 | 0.79 | P2RX7 (0.35) | P2RX7RHEB | |
| SCHEMBL830446 | 0.74 | RHEB (0.50) | P2RX7RHEBAHRF7LTA4H | |
| SCHEMBL31416308 | 0.74 | RHEB (0.50) | P2RX7RHEBAHRF7LTA4H | |
| SCHEMBL27894949 | 0.73 | AHR (0.55) | RHEBAHRGPR84 | |
| SCHEMBL8529419 | 0.71 | AXL (0.48) | P2RX7RHEBAHRF7LTA4H | |
| SCHEMBL8528766 | 0.71 | RHEB (0.40) | P2RX7RHEBAHRF7LTA4H | |
| SCHEMBL1065531 | 0.71 | AHR (0.52) | P2RX7RHEBAHRF7LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | P2RX7 1891/4885RHEB 1559/4885AHR 1587/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | P2RX7 1891/4885RHEB 1559/4885AHR 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.